Status: Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Participants needed: 180
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ModeX Therapeutics, An OPKO Health CompanyUpdated: May 4, 2026Locations: 2
Eligibility criteria
Participant must be ≥ 18 years of age. [+8]
Known or suspected history of hemophagocytic lymphohistiocytosis (HLH). [+8]